EA201600128A1 - 2-AMINO-1-HYDROXYETHYL-8-HYDROXYHINOLIN-2 (1H) -ONA SALTS, OWNER OF THE ANTAGONISTIC ACTIVITIES - Google Patents

2-AMINO-1-HYDROXYETHYL-8-HYDROXYHINOLIN-2 (1H) -ONA SALTS, OWNER OF THE ANTAGONISTIC ACTIVITIES

Info

Publication number
EA201600128A1
EA201600128A1 EA201600128A EA201600128A EA201600128A1 EA 201600128 A1 EA201600128 A1 EA 201600128A1 EA 201600128 A EA201600128 A EA 201600128A EA 201600128 A EA201600128 A EA 201600128A EA 201600128 A1 EA201600128 A1 EA 201600128A1
Authority
EA
Eurasian Patent Office
Prior art keywords
salts
hydroxyhinolin
ona
owner
hydroxyethyl
Prior art date
Application number
EA201600128A
Other languages
Russian (ru)
Other versions
EA035436B1 (en
Inventor
Монтсеррат Хулия Хане
Франсеск Каррера Каррера
Мария Прат Киньонес
Карлос Пуиг Дуран
Франсеска Пахуэло Лоренсо
Хуан Антонио Перес Андрес
Original Assignee
Альмираль, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48917474&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201600128(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Альмираль, С.А. filed Critical Альмираль, С.А.
Publication of EA201600128A1 publication Critical patent/EA201600128A1/en
Publication of EA035436B1 publication Critical patent/EA035436B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

В заявке описаны кристаллические соли присоединения (i) производных 8-гидроксихинолин-2(1Н)-она с (ii) дикарбоновой кислотой или сульфимидом или их фармацевтически приемлемые сольваты.The application describes crystalline addition salts (i) of 8-hydroxyquinoline-2 (1H) -one derivatives with (ii) dicarboxylic acid or sulfimide, or their pharmaceutically acceptable solvates.

EA201600128A 2013-07-25 2014-07-24 Crystalline addition salt of trans-4-[{3-[5-({[(2r)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}methyl)-1h-1,2,3-benzotriazol-1-yl]propyl}(methyl)amino]cyclohexylhydroxy(di-2-thienyl)acetate saccharinate having both muscarinic receptor antagonist and beta-2 adrenergic receptor agonist activities EA035436B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382304 2013-07-25
PCT/EP2014/065965 WO2015011244A1 (en) 2013-07-25 2014-07-24 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES

Publications (2)

Publication Number Publication Date
EA201600128A1 true EA201600128A1 (en) 2016-07-29
EA035436B1 EA035436B1 (en) 2020-06-15

Family

ID=48917474

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201600128A EA035436B1 (en) 2013-07-25 2014-07-24 Crystalline addition salt of trans-4-[{3-[5-({[(2r)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}methyl)-1h-1,2,3-benzotriazol-1-yl]propyl}(methyl)amino]cyclohexylhydroxy(di-2-thienyl)acetate saccharinate having both muscarinic receptor antagonist and beta-2 adrenergic receptor agonist activities

Country Status (36)

Country Link
US (1) US9579316B2 (en)
EP (1) EP3024489B1 (en)
JP (1) JP6374962B2 (en)
KR (1) KR102338155B1 (en)
CN (2) CN112321579A (en)
AR (1) AR097079A1 (en)
AU (1) AU2014295028B2 (en)
BR (1) BR112016001295B1 (en)
CA (1) CA2917596C (en)
CL (1) CL2016000187A1 (en)
CR (1) CR20160043A (en)
CY (1) CY1122920T1 (en)
DK (1) DK3024489T3 (en)
DO (1) DOP2016000011A (en)
EA (1) EA035436B1 (en)
ES (1) ES2788627T3 (en)
HK (1) HK1219043A1 (en)
HR (1) HRP20200670T1 (en)
HU (1) HUE049441T2 (en)
IL (1) IL243173B (en)
LT (1) LT3024489T (en)
MX (1) MX360837B (en)
MY (1) MY184681A (en)
NI (1) NI201600012A (en)
NZ (1) NZ715128A (en)
PE (1) PE20160173A1 (en)
PH (1) PH12016500125B1 (en)
PL (1) PL3024489T3 (en)
PT (1) PT3024489T (en)
RS (1) RS60185B1 (en)
SG (1) SG11201510682YA (en)
SI (1) SI3024489T1 (en)
TW (1) TWI641373B (en)
UY (1) UY35678A (en)
WO (1) WO2015011244A1 (en)
ZA (1) ZA201509203B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
SG11201504452WA (en) 2012-12-18 2015-07-30 Almirall Sa New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
TWI643853B (en) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH β2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES
CN105473133A (en) 2013-04-30 2016-04-06 欧缇托匹克公司 Dry powder formulations and methods of use
TW201517906A (en) 2013-07-25 2015-05-16 Almirall Sa Combinations comprising MABA compounds and corticosteroids
TWI641373B (en) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES
TW201617343A (en) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 New bicyclic derivatives having [beta]2 adrenergic agonist and M3 muscarinic antagonist activities
CN107074833B (en) * 2015-07-21 2021-05-25 四川海思科制药有限公司 Having beta2Benzo ring derivatives with receptor agonistic and M3 receptor antagonistic activities and application thereof in medicine
CN106554350B (en) * 2015-09-29 2019-12-20 四川海思科制药有限公司 Benzo heterocyclic derivative with beta 2 agonist activity and its prepn and application
TW201835041A (en) * 2017-02-17 2018-10-01 印度商托仁特生技有限公司 Compounds with Beta-Adrenergic Agonist and Antimuscarinic Activity
KR20230040375A (en) 2017-09-22 2023-03-22 오티토픽 인코퍼레이티드 Dry powder compositions with magnesium stearate
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CN113544121A (en) * 2019-06-06 2021-10-22 中国医药研究开发中心有限公司 Heterocyclic derivative with beta 2 receptor agonistic and M receptor antagonistic activities and medical application thereof
US20230322745A1 (en) * 2020-09-28 2023-10-12 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Fused tricyclic derivative and pharmaceutical application thereof
WO2023179758A1 (en) * 2022-03-25 2023-09-28 正大天晴药业集团股份有限公司 Crystal of fused tricyclic derivative or pharmaceutically acceptable salt thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1212742B (en) 1983-05-17 1989-11-30 Dompe Farmaceutici Spa DIBENZO DERIVATIVES [1,4] PYRID DIAZEPINONIC [1,4] BENZODIAZEPINONIC, PYRID [1,5] BENZODIAZEPINONIC AND THEIR PHARMACOLOGICAL ACTIVITY
ATE25966T1 (en) 1983-09-26 1987-04-15 Magis Farmaceutici AMINOCYCLOHEXANOL DERIVATIVES WITH EXPECTORANT ACTIVITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
JPH03178929A (en) 1989-09-07 1991-08-02 Glaxo Group Ltd Therapeutic compound for treating inflammation and allergy
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
WO1998009632A1 (en) 1996-09-06 1998-03-12 Merck & Co., Inc. Methods and compositions for treating preterm labor
SE9704644D0 (en) 1997-12-12 1997-12-12 Astra Ab New use
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
WO2001014339A2 (en) 1999-08-20 2001-03-01 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
US6806314B2 (en) 2003-02-03 2004-10-19 Ppg Industries Ohio, Inc. Coating of Hydroxy-functional polymer(s), crosslinker, and 1,3- and 1,4-cyclohexane dimethanols
PE20040950A1 (en) 2003-02-14 2005-01-01 Theravance Inc BIPHENYL DERIVATIVES AS AGONISTS OF ß2-ADRENERGIC RECEPTORS AND AS ANTAGONISTS OF MUSCARINAL RECEPTORS
EP1615881A2 (en) 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP1626970B1 (en) 2003-05-28 2009-07-08 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
WO2005080375A1 (en) 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
DE102004024453A1 (en) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg New long-acting bronchodilators for the treatment of respiratory diseases
ES2251867B1 (en) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
JP2008510015A (en) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド Compounds having β2 adrenergic receptor agonist activity and muscarinic receptor antagonist activity
US7528253B2 (en) 2004-08-16 2009-05-05 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
RU2442771C2 (en) 2005-08-08 2012-02-20 Арджента Дискавери Лтд Derivants of bicyclo[2, 2, 1] hept-7-ylamine and their applications
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
MX2008011963A (en) 2006-03-20 2008-10-01 Pfizer Ltd Amine derivatives.
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
WO2008017827A2 (en) 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
GB0702384D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Chemical compounds
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
JP2010505810A (en) 2006-10-04 2010-02-25 ファイザー・リミテッド Sulfonamide derivatives as adrenergic and muscarinic antagonists
GB0700972D0 (en) 2007-01-18 2007-02-28 Imp Innovations Ltd Treatment of inflammatory disease
GB0702413D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
WO2008149110A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Limited Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
UY31235A1 (en) 2007-07-21 2009-03-02 NEW PULVERULENT DRUGS CONTAINING TIOTROPY AND SALMETEROL, AS WELL AS LACTOSE AS EXCIPIENT
WO2009017813A1 (en) * 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
MY149731A (en) 2008-02-06 2013-10-14 Astrazeneca Ab Compounds
CN101544572B (en) 2008-03-26 2013-03-20 连云港恒邦医药科技有限公司 Ambroxol derivative and method for preparing same
GB0808708D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
EP2303266A4 (en) * 2008-06-20 2015-01-21 Astrazeneca Ab Pharmaceutical composition comprising a 4-hydroxy-2-oxo-2, 3- dihydro-1, 3-benzothiazol-7-yl compound for modulation of beta2-adrenoreceptor activity
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
PT2599778T (en) 2009-04-23 2017-06-06 Theravance Respiratory Co Llc Diamide compounds having muscarinic receptor antagonist and beta 2 adrenergic receptor agonist activity
EP2426121A4 (en) 2009-04-30 2012-10-31 Teijin Pharma Ltd Quaternary ammonium salt compound
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
GB201002612D0 (en) * 2010-02-16 2010-03-31 Jagotec Ag Improvements in or relating to organic compounds
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (en) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire PLATE FOR THE CONSTRUCTION OF TRUCKS FOR AIRPLANES
AR083115A1 (en) 2010-09-30 2013-01-30 Theravance Inc CRYSTAL OXALATE SALTS OF A DIAMID COMPOUND
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
RU2606121C2 (en) 2011-06-10 2017-01-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Compounds having antagonistic activity towards muscarinic receptors and agonist activity to beta2-adrenoreceptors
EP2718280B1 (en) 2011-06-10 2015-09-16 Chiesi Farmaceutici S.p.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN104105485B (en) 2011-11-11 2017-04-12 吉利德阿波罗公司 Acc inhibitors and uses thereof
UA108713C2 (en) 2011-11-11 2015-05-25 2-Thiopyrimidinones
EP2592077A1 (en) * 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
UA111867C2 (en) 2011-11-11 2016-06-24 Аллерган, Інк. PHARMACEUTICAL COMPOSITION AND METHOD OF APPLICATION OF 4-PROGEN-11β-17-21-TRIOL-3,20-DION DERIVATIVES
TW201427977A (en) 2012-12-06 2014-07-16 Chiesi Farma Spa Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
DK3345904T3 (en) 2012-12-06 2020-08-31 Chiesi Farm Spa Compounds with muscarinic receptor antagonist and beta2-adrenergic receptor agonist activity
SG11201504452WA (en) 2012-12-18 2015-07-30 Almirall Sa New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
TW201440768A (en) 2013-02-27 2014-11-01 Almirall Sa Combinations comprising MABA compounds and corticosteroids
TWI643853B (en) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH β2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES
TW201517906A (en) 2013-07-25 2015-05-16 Almirall Sa Combinations comprising MABA compounds and corticosteroids
TWI641373B (en) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES
TW201617343A (en) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 New bicyclic derivatives having [beta]2 adrenergic agonist and M3 muscarinic antagonist activities

Also Published As

Publication number Publication date
PH12016500125A1 (en) 2016-04-25
BR112016001295B1 (en) 2022-07-19
CN112321579A (en) 2021-02-05
MX2016000397A (en) 2016-04-29
AU2014295028A1 (en) 2016-01-21
EP3024489B1 (en) 2020-02-19
IL243173B (en) 2019-10-31
PE20160173A1 (en) 2016-04-13
PH12016500125B1 (en) 2016-04-25
EP3024489A1 (en) 2016-06-01
AU2014295028B2 (en) 2018-05-31
TW201517907A (en) 2015-05-16
ZA201509203B (en) 2017-04-26
JP6374962B2 (en) 2018-08-15
BR112016001295A2 (en) 2017-07-25
MX360837B (en) 2018-11-20
CY1122920T1 (en) 2021-10-29
SI3024489T1 (en) 2020-04-30
NI201600012A (en) 2016-10-10
CA2917596C (en) 2021-06-22
SG11201510682YA (en) 2016-02-26
ES2788627T3 (en) 2020-10-22
NZ715128A (en) 2019-03-29
PT3024489T (en) 2020-05-05
RS60185B1 (en) 2020-06-30
JP2016525533A (en) 2016-08-25
PL3024489T3 (en) 2020-08-10
KR20160034310A (en) 2016-03-29
UY35678A (en) 2015-02-27
WO2015011244A1 (en) 2015-01-29
CR20160043A (en) 2016-04-08
US20160166566A1 (en) 2016-06-16
MY184681A (en) 2021-04-16
TWI641373B (en) 2018-11-21
HUE049441T2 (en) 2020-09-28
CN105492027A (en) 2016-04-13
IL243173A0 (en) 2016-02-29
HK1219043A1 (en) 2017-03-24
KR102338155B1 (en) 2021-12-10
LT3024489T (en) 2020-03-10
CL2016000187A1 (en) 2016-08-05
DK3024489T3 (en) 2020-05-04
HRP20200670T1 (en) 2020-07-10
DOP2016000011A (en) 2016-06-15
US9579316B2 (en) 2017-02-28
AR097079A1 (en) 2016-02-17
CA2917596A1 (en) 2015-01-29
EA035436B1 (en) 2020-06-15

Similar Documents

Publication Publication Date Title
EA201600128A1 (en) 2-AMINO-1-HYDROXYETHYL-8-HYDROXYHINOLIN-2 (1H) -ONA SALTS, OWNER OF THE ANTAGONISTIC ACTIVITIES
EA201500875A1 (en) DERIVATIVES OF THE STATE
CL2017001566A1 (en) Azabicycloothane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases.
NI201600152A (en) FUSED BICYCLIC HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS
DK3359542T3 (en) SPIRO [3H-INDOL-3,2'-PYRROLIDIN] -2 (1H) -ON COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS
CY1124800T1 (en) PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
UY35834A (en) PIPERAZINAS DE PIRAZOLO REPLACED AS INHIBITORS OF CASEÍNA QUINASA 1 DELTA AND EPSILON
CR20150524A (en) HETEROARILO COMPOUNDS AND ITS USES
MY192467A (en) 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their use as herbicides
EA201790395A1 (en) AMINOTRIAZIN DERIVATIVES SUITABLE FOR USING AS TANK-BINDING KINASE INHIBITORS
EA201692465A1 (en) CRYSTALLINE SALTS (S) -6 - ((1-ACETYLPIPERIDIN-4-IL) AMINO) -N- (3- (3,4-DIHYDRO-ISOHINOLIN-2 (1H) -YL) -2-HYDROXYPROPIL) Pyrimidine-4-C-Cyropyridine-4-Cyropyridine-4-Cylindiol-4-IL-2).
MX2014001885A (en) 5-FLUORO-4-IMINO-3-(SUBSTITUTED)-3,4-DIHYDROPYRIMIDIN-2-(1H</ i>)-ONE DERIVATIVES.
DK3287460T3 (en) HEMISULPHATE SALT OF 5,10-METHYLENE- (6R) -TETRAHYDROFOLIC ACID
UY35274A (en) COMPOUNDS AND METHODS TO TREAT BACTERIAL INFECTIONS
EA201790432A1 (en) PROBES FOR VISUALIZATION PROTEIN HANTINGTIN
EA201592183A1 (en) BACE INHIBITORS
EA201790939A1 (en) TRIAZOLO [4,5-d] Pyrimidine as an agonist of cannabinoid receptor type 2
EA201400822A1 (en) DERIVATIVES OF HETEROCYCLIC AMIDES AS AN ANTAGONISTS OF P2HRECEPTOR
BR112016027691A2 (en) TETRAHYDROPYRIDOPYRIMIDINE COMPOUND AND ITS USES
EA201591939A1 (en) Pyrrolo [2,3-d] pyrimidine derivatives as agonists of CB2 receptor
CR20160070A (en) TRIAZOLOPIRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE OF THE SAME
RS54716B1 (en) Heterocyclic compounds and their uses
EA201790687A1 (en) QUINOLINCARBOXAMIDE FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA
EA201491227A1 (en) NEW MORFOLINIL DERIVATIVES SUITABLE FOR USING AS MOGAT-2 INHIBITORS

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG TJ TM